A negative flecainide challenge does not definitively exclude Brugada syndrome in patients with aborted sudden cardiac death, highlighting the need for long-term ECG follow-up and potential repeat testing.
Answers are grounded in this paper and cite their sources.
Negative flecainide challenges may miss Brugada syndrome post-arrest; leaves open optimal diagnostic protocols and serial testing needs.
A negative flecainide challenge does not rule out Brugada syndrome even in the presence of nonfatal cardiac arrest as the first manifestation of the disease. This should prompt clinicians to ensure long-term ECG follow-up and consider repeating a drug test with another sodium channel blocker.
No takes yet. Share an insight, caveat, or question.
Chauveau et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: